Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 18113.50%.
Infravalorada
El PE más reciente de la empresa es -8.47, en un rango percentil bajo de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 216.89M acciones, lo que supone un aumento del 18.71% con respecto al trimestre anterior.
Menor actividad del mercado
La empresa está generando menos interés entre los inversores, con una relación de rotación de 20 días del %!.(string=-0.23)